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Malignant transformation from normal to cancerous tissue is asso-
ciated with cell-surface glycoprotein and glycolipid modifications
(Hakomori, 1989). These glycoconjugates can be released in the
circulation through increased cell turnover, secretion or shedding
from the malignant cells and have been considered as potential
tumour markers for helping in screening, diagnosis, staging,
prognosis and monitoring of cancer therapy (Cohn et al, 1986).
The protease dipeptidyl peptidase IV (DPP-IV, EC 3.4.14.5.) is a
110 000 MW cell-surface glycoprotein expressed on a variety of
cell types, particularly melanocytes, epithelial cells (Iwata and
Morimoto, 1999) and lymphocytes, where DPP-IV is necessary
for normal immune function (see review, De Meester et al, 1999)
and was assigned to the CD26 cluster. CD26 is a functional
receptor for collagen (Bauvois, 1988; Dang et al, 1990) and was
also recently identified as the adenosine deaminase binding or
complexing protein (ADAbp, ADCP) (Kameoka et al, 1993; De
Meester et al, 1994). Significant levels of DPP-IV activity have
been shown to exist in plasma, serum and urine (Sharpé et al,
1988). The MW of serum CD26 (sCD26) suggests that it is
originated by a shedding of membrane CD26 (Iwaki-Egawa et al,
1998). sCD26 can cleave NH2-terminal dipeptides from polypep-
tides with either L-proline or L-alanine at the penultimate position
(Fleischer, 1994). Many biologically active polypeptides have 
this sequence, for example substance P, chorionic gonadotropin,
monomeric fibrin, promellitin (Bauvois et al, 1992) and regulatory
peptides such as glucagon-like peptides 1 and 2 (Drucker et al,
1997). A proline residue is also present at the P1 position in many
cytokines, such as IL-1β , IL-2, IL-6, and G-CSF (Ansorge et al,
1991). CD26 enzymatic activity also affects TNF-α (Bauvois et al,
1992), neuropeptides such as Y and YY (Medeiros and Turner, 1994)
and chemokines activity (Oravecz et al, 1997; Proost et al, 1998).
CD26, when known as ADCP, was described to be consistently
associated with cancer. The loss of DPP-IV expression during
malignant transformation has been best characterized in
melanocytic cells, although a role for DPP-IV in regulating the
malignant phenotype had not been shown until very recently
(Iwata and Morimoto, 1999; Wesley et al, 1999). A deficiency in
solubilized CD26 was reported in total homogenates of tumours of
colon, kidney, lung and liver (Ten Kate et al, 1985; 1986a), as well
as in different transformed or cancer-derived cell lines (Ten Kate
et al, 1986b). On the contrary, cell-surface CD26 expression 
has been correlated with disease aggressiveness of T and B cell
lymphomas and leukaemias, follicular cell-derived thyroid
carcinomas and basal cell carcinomas (reviewed in Iwata and
Morimoto, 1999). In addition, serum DPP-IV activity was
increased in patients with hepatic cancer (Hino et al, 1975; Kojima
et al, 1987), and decreased in patients with blood, solid and oral
(Fujita et al, 1977; Mogi et al, 1986; Uematsu et al, 1996) cancer.
From these data, it seems helpful to fully evaluate the potential
significance of serum CD26 as a colon carcinoma (which 
remains a major medical problem) (American Society of Clinical
Oncology, 1996; 1998) diagnostic and prognostic marker.
MATERIALS AND METHODS
Patients
Preoperative blood and primary tumour samples were collected
between January 1994 and December 1997 from 110 potentially
curable patients (56 females, 54 males, mean age 68, range
34–88), operated for colorectal cancer (74 colon, 36 rectum) in the
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patients from the same hospital with other diseases were also
studied: nine patients with gastrict tract carcinomas, five patients
with Crohn’s disease, five patients with benign pathology of the
gastric tract and four patients with blood cell cancer. The control
group, consisting of 52 healthy blood donors (23 females, 29
males) was provided by the Centro de Transfusion de Galicia
throughout 1997. Some data of the population samples came from
other studies (Fernández-Rodríguez et al, 2000; Ayude et al,
2000).
For prognostic studies, no patient receiving adjuvant therapy
either preoperatively or postoperatively was included. Patients
with family adenomatous polyposis coli, inflammatory bowel
disease, or previous colorectal cancer were not included for
review. The presence of metastasis or the failure to resect all the
tumour deemed the resection palliative and these patients were
excluded from analysis, as were those who died within 30 days 
of surgery. Thus, only 87 potentially cured patients with Dukes’
stages A–C were followed-up for 2 years until recurrence.
Preparation of samples
The drawn blood was allowed to coagulate at room temperature
and centrifuged at 2000 g for 15 min. The sera were stored at
–85° C until used. All adenocarcinoma samples were processed for
regular pathological and histological examination.
Immunoassays
The concentration of serum CD26 and carcinoembryonic antigen
(CEA) were analysed using specific immunoassays (human soluble
CD26 ELISA Kit from Bender Medsystems, Vienna, Austria,
and Enzymun-Test CEA from Boehringer Mannheim, Germany).
ELISAs were performed according to the manufacturer’s instruc-
tions: mean values of duplicated measurements were calculated and
a sigmoid-shaped standard curve was determined by simultane-
ously analysing a dilution series of standard samples. Specificity of
sCD26 system was evaluated by the manufacturer for several circu-
lating factors of the immune system and no cross-reactivity was
detected. No cross-reactivity of anti-sCD26 Abs with rheumatoid
factor was found in a previous study (manuscript submitted).
Prognostic predictors
Five clinical and pathological variables were evaluated according
to the following definitions: age, sex, tumour location, stage, and
degree of differentiation. Age was recorded in years at time of
operative intervention; for statistical analysis, patients were
grouped into two categories, ≤ 50 and > 50 years old. For the
recurrence study, the cut-off chosen was ≤ 76 or > 76, to better
discriminate the two groups. Recurrence pattern based on patients’
sex was also analysed. The site of the primary lesion was deter-
mined from the operative report. The large-bowel was divided into
two regions for statistical analysis: colon (including right and left
colon, and sigma) and rectum (lesions were considered rectal if
their origin was below the peritoneal reflection). The stage of
disease was originally reported using Dukes’ classification (inva-
sive and metastatic potential of tumours) (Dukes, 1932) as deter-
mined in the original operation. The degree of differentiation as
described by the pathologist in the original operation was recorded
and classified into three categories: well, moderately and poorly
differentiated lesions.
Statistical methods
Normal distribution was assessed using the Kolmogorov-Smirnov
test. Variance homogeneity was evaluated by the Levene test. 
The statistical significance of the results was assessed using 
a nonpaired Student’s t-test or Mann–Whitney U test performed 
in the SPSS program for Windows (Release 7.5.2S, or 8.0).
Statistical comparisons among groups were made by
Kruskal–Wallis and ANOVA tests, according to the Levene test
results, respectively. A cut-off value for CD26 was determined
using receiver operating characteristics (ROC). ROC curves are
plots of the percentage true-positives (sensitivity) against the
percentage false-positives (100-specificity) for multiple thresholds
(Beck and Shultz, 1986; Zweig and Campbell, 1993). In order to
evaluate the impact of each variable over the disease-free inter-
val, a postoperative follow-up of the patients was performed.
Kaplan–Meier curves (Kaplan and Meier, 1958) were constructed,
with colorectal cancer-related recurrence as the primary end-point.
Differences in disease-free survival (DFS) among groups were
assessed by log-rank analysis. P values ≤ 0.05 were considered
statistically significant.
RESULTS
sCD26 levels in serum of healthy donors and patients
with colorectal cancer
Soluble CD26 concentration (µ g l–1) was determined in 110 sera
from patients with colorectal cancer and 52 control sera from
healthy donors. Data from both populations follow a normal distri-
bution. The concentration of sCD26 was dramatically impaired in
many colorectal cancer patients (261.65 ± 138.07 µ g l–1, range
56–980 µ g l–1) with respect to control donors (559.65 ± 125.52 µ g
l–1, range 273–863 µ g l–1), on average by 53% (P < 0.001).
Statistical analysis after this comparison gave the results shown
in Table 1. There were no significant differences between the two
sex- and age-groups for both donor and patient samples, which is
particularly interesting in the second case, due to the strong differ-
ence between donor and patient samples in the number of recruited
individuals for both age-groups. These data agree with the fact that
DPP-IV activities did not differ significantly with age (Hino et al,
1975).
Relationship between preoperative serum sCD26 levels
and clinicomorphologic features of tumours
Table 2 compares by the Kruskal–Wallis test preoperative serum
sCD26 levels and the Dukes’ stages from patients with colorectal
adenocarcinoma. In addition, statistical comparisons between
groups were made by using the Mann–Whitney U test, as there
was not variance homogeneity. By these analyses, there is no
difference in the preoperative serum activity of sCD26 among
Dukes’ stages. The possible association between preoperative
serum sCD26 levels and age, sex, tumour location and degree 
of histologic differentiation of tumours was also examined.
According to our data (Tables 1, 2 and 3) none of these properties
was correlated with preoperative serum sCD26 levels.
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carcinomas and benign diseases
The level of sCD26 was also determined in serum of 23 patients
with related diseases other than colorectal cancer, preliminarily to
check the specificity of our finding. These patients were included
in three different groups: patients with gastric-tract carcinomas
(GC, n = 9), patients with blood cell cancer (BCC, n = 4) and
patients with Crohn’s disease or with benign pathology of the
gastric tract (BPI, n = 10). Results shown in Figure 1 suggest that
sCD26 levels discriminate well colorectal carcinoma from gastric
(585 ± 148 µ g L–1) and blood cell cancer (663 ± 196 µ g l–1), and
that a study on sCD26 in different BCCs could clear the origin of
sCD26 because its levels are enhanced in some but not in other
BCCs. Curiously, the majority of BPI show low sCD26 levels
whereas Crohn’s patients presented a very irregular distribution.
Diagnostic efficiency of sCD26 preoperative serum
levels
Receiver operating characteristics (ROC) curves for sCD26 and
CEA are represented in Figure 2. The corresponding sensitivities
at different specificity levels for sCD26 are provided in Table 4.
The ideal cut-off point for diagnostic value of sCD26 was deter-
mined by random selection of outstanding points from the ROC
curve. The best efficiency (90%) was obtained with the point 
410 µ g l–1, representing a sensitivity of 90% with a specificity of
90%. Even with a specificity of the 100% the efficiency is good
(71%). This curve revealed that the diagnostic efficiency of sCD26
levels is higher than that shown by CEA, the more extensively
used in health services, which showed an efficiency of the 69%.
We also studied the diagnostic efficacy of sCD26 in Dukes’ stages
A, B, C and D patients. Figure 3 shows that the sensitivity is
enhanced in the A, B and C stages, whereas was impaired in the
Dukes’ stage D, in which CEA levels diagnosed better.
sCD26 as prognostic predictor in colorectal cancer
From the 110 patients with colorectal adenocarcinoma included in
this work, only 87 potentially cured patients with Dukes’ stages
A–C were followed-up for at least 1 year or until recurrence. After
a mean postoperative follow-up period of 22 months, recurrence
appeared in 18 patients. Disease-free survival time was 39 months
(mean confidence interval, 35–43, maximum 49, n = 87) and the
percentage of tumoural recurrence was 21.1%. The survival curve
of the total potentially cured patients included in this study is
plotted in Figure 4A. The same study was performed considering
only patients in Dukes’ stage B (Figure 4B) or C (data not shown)
(there was not enough data for A), finding a non-significant result
and a particularly bad behaviour of sCD26 as a prognostic marker
in Dukes’ stage C. Table 5 shows the results of a univariate
survival analysis of patients stratified into groups by biochemical,
clinical and pathological features. From these parameters, only the
Dukes’ stages, as currently described, and sCD26 were related to
sCD26 as diagnostic and prognostic marker in CRC patients 1141
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Table 1 Serum CD26 concentration in donors and patients with colorectal cancer
Case n Mean ± SD SEM Range Student’s t-test
(µ g l–1)
Donors 52 559.65 ± 125.53 17.41 273–863
Sex
Men 23 584.70 ± 113.93 23.76
NS
Women 29 539.79 ± 132.58 24.62
Age
< 50 years 39 557.36 ± 126.31 20.23
NS
≥ 50 years 13 566.54 ± 127.95 35.49
P < 0.001
Tumoural 110 261.65 ± 138.07 12.45 56–980
Sex
Men 56 235.77 ± 101.71 13.59
NS
Women 54 273.52 ± 155.92 21.22
Age
< 50 years 9 218.56 ± 77.42 25.81
NS
≥ 50 years 101 257.49 ± 135.50 13.48
NS = not significant; P = statistical significance. The age cut-off point (50 years) was chosen because it can be used in both donor and
tumoural groups, facilitating comparison
Table 2 Relationship between the levels of sCD26 and the Dukes’ stage classification
Dukes’ stage n Mean ± SD (µ g l–1) SEM Median Range Kruskal–Wallis test
A 12 295.33 ± 152.34 43.98 292 78–663
B 55 226.67 ± 93.06 12.55 205 100–438 NS
C 29 251.48 ± 95.45 17.73 248 78–522
D 14 333.50 ± 243.10 64.97 312 56–980
NS = not significantlong-term outcome in this study. For sCD26, two groups of
patients could be differentiated choosing the cut-off in the 60th
percentile (250 µ g l–1), the log-rank test giving a P = 0.0346. Data
from the survival curves of Figure 4 and the fact that age and
degree of differentiation (Table 5) are near to significance in this
work, are encouraging us to study a larger follow-up period.
DISCUSSION
Cell-surface proteases participate in malignant transformation 
and cancer progression by facilitating invasion and metastasis.
However, they may also have the opposite effect. This is the case
for DPP-IV/CD26 (Werb, 1997; Iwata and Morimoto, 1999). The
diverse biological functions of CD26 (De Meester et al, 1999;
Iwata and Morimoto, 1999) may be responsible in part for the
different roles of CD26 in various clinical settings. In melanoma
cells, where membrane expression of DPP-IV is, as well as in
CRC, lost or altered (Ten Kate et al, 1986a; Morrison et al, 1993),
it has been demonstrated that the inducible translation of CD26
reverses the malignant phenotype. It is suggested that DPP-IV
enzymatic activity degrades growth factors (unknown autocrine
factors, although candidates should be among those cited in the
introduction) required for survival of tumour cells.
Surprisingly, little information is available about the physio-
logical activity of sCD26 in spite of its presence at relatively high
concentrations in serum (~ 600 µ g l–1) of healthy donors. Studies
like this should unravel the kind of cells which shed membrane
CD26 to the serum. For example, as membrane CD26 is lost in
hepatocellular carcinoma (Ten Kate et al, 1985; Iwata and
Morimoto, 1999; Perner et al, 1999) and DPP-IV is increased in
patients with hepatic cancer (Kojima et al, 1987) as well as in
many studies of hepatic regeneration, liver epithelia is one of 
the suggested sCD26 sources. In this case, sCD26 levels would
correlate with cell proliferation. This is clearly not the case for
colorectal carcinoma as well as, our data suggest, for other
pathologies such as the GC group. The studies on the membrane
CD26 in human CRC (Ten Kate et al, 1985; 1986b) found a loss of
expression in only 11% of the patients, and decreases in a third of
the patients. Although this and our study, in which 58% of patients
had lower values than the minimum range of normal donors,
cannot be directly correlated, it is easily deduced that loss of
membrane CD26 and enhancement of sCD26 are not correlated in
1142 OJ Cordero et al
British Journal of Cancer (2000) 83(9), 1139–1146 © 2000 Cancer Research Campaign
Table 3 Relationships between preoperative sCD26 levels and the degree of tumour differentiation or location
n Mean ± SD (µ g l–1) SEM ANOVA
Degree of
differentiation
Good 10 257.30 ± 86.28 27.28
Moderate 90 247.83 ± 112.92 11.90 NS
Poor 9 235.00 ± 141.82 47.27
Location Student’s t
Colon 74 251.24 ± 141.69 16.47
NS
Rectum 36 260.58 ± 110.69 18.45
NS = statistically not significant. With regard to the degree of differentiation, information from one patient was lost
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Figure 1 Serum CD26 (µ g l–1) in healthy donors and patients with:
colorectal cancer (CRC), gastric-tract carcinoma (GC), Crohn’s disease and
other benign pathology of intestinal tract (BPI), and blood cell cancer (BCC).
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Figure 2 ROC curves for the serum levels of CD26 and CEACRC. In addition, we found a lack of any direct correlation of
sCD26 with tumour location, degree of histologic differentiation,
kind of metastasis or Dukes’ stages. In conclusion from all these
data, 53% impairment in sCD26 in colorectal cancer does not seem
to be originated by alteration of CD26 on CRC tumour cells.
At least two possibilities arise from this conclusion: that CRC,
as well as BPI but not GC, is associated with an impairment of the
usual hepatic function, or the drop in sCD26 levels is related to the
immune system status. For the first case, no data have been
published up to now. In fact, as CRC metastases were each all
located in liver, an improvement in sCD26 levels should be
expected, as well as a correlation with the kind of metastasis.
However, a cross-talk between the lymphoid lineage and malig-
nant tumours in vivo have been long discussed (Shibuya-Saruta et
al, 1996; Gruss et al, 1997; Nano et al, 1997; Iwata and Morimoto,
1999) and some data about the immune defective antitumour
response in CRC have been described before, including a defect in
IL-12 production (O’Hara et al, 1998), which is a well-known
CD26 up-regulator (Cordero et al, 1997) on T cells. In oral cancer
patients, in which around a 50% decrease in serum DPP-IV
activity has been reported, a correlation between sCD26 and
CD26+ T was found, and the number of T lymphocytes and PBL
and the amount of CD26 in T lymphocyte plasma membranes were
significantly less than in healthy subjects (Uematsu et al, 1996;
1998). Both possibilities can explain the donor-dependent varia-
tions, but the second one seems more probable in the cases of
hemicolectomy or rectoragy (some of the lower values of the BPI
group), except the Dukes’ stage D cases with high sCD26 values,
perhaps associated with a high proliferative (hepatic) cellular state,
or with a later activation of PBL as suggested in CRC and ovarian
tumours for the soluble CD44v6 glycoprotein (Sliutz et al, 1995;
Yamane et al, 1999). It seems, then, necessary to collect the
lymphocyte count and other immune parameters of the patients in
future studies of CRC. As some studies are showing that sCD26
therapy enhances the immune function in some pathological
conditions such as AIDS (Schmitz et al, 1996), it might be inter-
esting to analyse if CRC patients may well benefit from exogenous
sCD26 treatment.
Very recently, the clinical utility of serum DPP-IV/CD26
activity measurements was tested in adult and paediatric patients
with hepatobiliary diseases and in liver transplant recipients. The
results established elevated serum DPP-IV activity as a clinically
useful marker of cholestasis and demonstrate that DPP-IV levels
do not change in metastatic bone disease (Lakatos et al, 1999;
Perner et al, 1999) nor in allergic asthmatics, inhaling glucocorti-
coids or not (Van Der Velden et al, 1999). Higher activities were
also found in serum of patients with osteoporosis, probably related
to its severity (Gotoh et al, 1988). However, reduced peptidase can
be found in healthy smokers (Van Der Velden et al, 1999), alcohol-
dependent (Maes et al, 1999) and major depressive (Maes et al,
1997) donors. These last drops are also in agreement with an
impaired immune response. The studies described before show
alterations in the levels of the serum DPP-IV enzymatic activity.
To our knowledge, only one study reported a decrease of protein
sCD26 (but to a lesser extent than ours) in oral cancer patients
(Mogi et al, 1986), although the authors measured a higher quan-
tity of protein than we by using the commercial kit. In addition,
some of our data are not in accordance with published measure-
ments of DPP-IV enzymatic activities in some diseases such as GC
(lower levels than in normal subjects) (Hino et al, 1975), or in
some patients of the BCC group (Fujita et al, 1977). As at least one
different serum protein accounting for the DPP-IV activity (Duke-
Cohan et al, 1996) as well as new discovered cellular proteins with
DPP-IV activity (Pangalos et al, 1999; Underwood et al, 1999)
have been described, these facts should encourage more complete
studies at the protein level on different pathologies. Therefore,
although we found a normal distribution for sCD26 levels in both
samples of Spanish populations, which points to a unique locus for
the CD26 gene, a possible effect of race on the absolute levels
detected in this study cannot be excluded.
Establishing the diagnosis at an early stage in colorectal cancer,
with a simple biochemical index, is a current subject of research in
clinical oncology. The CEA levels are the marker of reference in
this neoplasia, although not recommended as diagnostic test for
CRC (American Society of Clinical Oncology, 1996). Our curve
revealed that sensitivities of sCD26 were higher at different speci-
ficity levels than those of CEA, as well as efficiency. Moreover,
when the diagnostic sensitivity of sCD26 and CEA by Dukes’
sCD26 as diagnostic and prognostic marker in CRC patients 1143
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Table 4 Comparison of three cut-off points for sCD26 (µ g l–1) in the detection of colorectal cancer
Positive Negative
Cut-off points Sensitivity Specificity predictive predictive Efficiency
(%) (%) value (%) value (%) (%)
270 µ g l–1 59 100 100 50 71
330 µ g l–1 80 94 97 67 85
410 µ g l–1 90 90 96 80 90
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Figure 3 Sensitivity of sCD26 and CEA serum levels for the diagnosis of
colorectal cancer by Dukes’ stagesstage were compared, sCD26 presents higher sensitivity than CEA
to diagnose patients in Dukes’ A, B and C stages. As recently
reported, serum TIMP-1 (plasma tissue inhibitor of metallopro-
teinase) or sCD44v6 screened better only the Dukes’ stage D CRC
(Holten-Andersen et al, 1999; Yamane et al, 1999), and serum
YKL-40 (Cintin et al, 1999) was clearly a poorer marker of
diagnosis. Our conclusion is that preoperative sCD26 level is an
useful, easy to handle marker for early detection of potentially
curable CRC.
Reported recurrence rates after curative resection of large-
bowel adenocarcinoma varied widely, partly because of how a
recurrence is defined (Stipa et al, 1991), from 3% to 50%, usually
within 2 years of surgery. As the risk factors commonly identified
(level of invasion, lymphatic involvement, and site of original
carcinoma) (Michelassi et al, 1990) do not always allow prediction
of the outcome, which may guide the physician in aggressive but
more selective adjuvant therapy and targeted surveillance in
follow-up (Obrand and Gordon, 1997), we also studied if CD26
can help to distinguish CRC cases at high risk of tumour recur-
rence. Two groups of patients were differentiated by placing a cut-
off point at the 60th percentile (log-rank test P = 0.0346).
According to our data there is no relationship between the preoper-
ative serum sCD26 levels and the classical clinical features
(Devesa et al, 1988). Meanwhile serum CEA levels, for example,
correlate with the degree of histologic differentiation and the
Dukes’ stages classification. Thus new information about the
prognosis of the patients is obtained. The different behaviour of
sCD26 values in prognosis of Dukes’ groups B and C can be also
explained by the hypothesis explained above, because in C, the
patients with an activation of the immune system (and thus with an
1144 OJ Cordero et al
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Table 5 Univariate analysis of the disease-free survival (DFS) according to the classical clinicopathological and
biochemical features of this study
Factor Category n DFS Tumoural Log-Rank
(months) recurrence (%) test (P)
Age
≤ 76 years 67 41.30 16.42 0.0561
> 76 years 20 29.55 35.00
Sex
Male 47 33.49 19.15 0.8103
Female 40 39.82 22.50
Location
Colon 59 39.93 16.95 0.1383
Rectum 28 32.35 28.57
Degree of
differentiation
Good 5 29.98 20.00
Moderate 76 39.54 19.42 0.0820
Poor 6 18.85 50.00
Dukes’ stage
A7 – 0
B 52 40.57 17.31 0.0299
C 28 25.33 32.14
sCD26
≤ 250 µ g l–1 52 33.73 26.92 0.0346
> 250 µ g l–1 35 38.97 11.43
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Figure 4 Kaplan–Meier recurrence curves for colorectal cancer patients stratified by the preoperative serum CD26 levels in (A) total patients, and (B) patients
of Dukes’ B. Group1 ( ) = Patients with sCD26 above 250 µ g l-1. Group 2 (---) = Patients with sCD26 equal or below 250 µ g l–1enhancement in their sCD26 levels) might show a better survival
than those with lower sCD26 values. The fact that analysis was
performed in 2 years of recurrence, that the measure is not related
with the pathological stage and can be carried out before the
surgical operation, appears nevertheless to justify a follow-up of
sCD26 as a prognostic variable.
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